Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Abstract Text:

PURPOSE: In this study, we tested the effectiveness of a melanoma-associated antigen-derived peptide, MART-1(27-35), in eliciting cellular immune responses in vivo in the context of a phase I active immunization protocol. This peptide (AAGIGILTV) corresponds to residues 27-35 from the nonmutated melanoma-associated antigen MART-1/Melan A and is recognized by most melanoma-specific, HLA-A*0201-restricted, tumor-infiltrating lymphocytes. To test the in vivo induction of cytotoxic T lymphocyte (CTL) sensitization, we compared CTL reactivity in vitro from peripheral blood mononuclear cell (PBMC) pools obtained before and after vaccination. PATIENTS AND METHODS: MART-1(27-35) was administered to HLA-A*0201 melanoma patients subcutaneously in an emulsification with incomplete Freund's adjuvant. A vaccination course included four inoculations of peptide at 3-week intervals. PBMC collected by leukapheresis and separated by Ficoll-Hypaque gradient before and after vaccination were analyzed in 18 patients by in vitro sensitization with MART-1(27-35). To induce MART-1(27-35)-specific CTL, PBMC were incubated with 1 microM peptide (on day 0) and interleukin-2 (IL-2) (300 IU/mL, on days 1 and 4 after each stimulation). At weekly intervals, cells were harvested and an aliquot was cryopreserved for later analysis. The remaining cells were replated and restimulated using irradiated autologous PBMC pulsed with 1 microM of relevant peptide. After three restimulations, all samples from one patient were tested simultaneously for HLA-A*0201-restricted anti-MART-1(27-35) reactivity by microcytotoxicity and cytokine (IFN-gamma) release assays. RESULTS: Toxicities were minimal and consisted of local irritation at the site of vaccine administration. None of the patients sustained a clinical response. The first eight patients were monitored by inducing CTL reactivity from PBMC obtained preimmunization and after two and four vaccinations. Only two prevaccination cultures were reactive to MART-1, compared with five and seven cultures from PBMC obtained after two and four vaccinations, respectively. Thus, an enhancement in cytotoxic activity could be detected in postvaccination CTL cultures, and serial vaccine administrations appeared to boost the detectability of cytotoxicity in vitro. For completeness, the analysis compared prevaccination with postvaccination PBMC cultures. Specific anti-MART-1(27-35) cytotoxicity (> or = 10 lytic units) could be detected in two prevaccination and 12 postvaccination cultures after two in vitro stimulations. In 15 postvaccination CTL cultures, a more than threefold increase in specific release of IFN-gamma was noted, compared with prevaccination. DISCUSSION: In vivo administration of a melanoma-associated antigen peptide, emulsified in incomplete Freund's adjuvant, could safely augment CTL reactivity against epitopes commonly expressed by melanoma cells. Although the enhancement of CTL reactivity did not achieve tumor regression, it is possible that the use of recombinant immunogens with increased immunomodulatory capabilities in future clinical trials could reach the threshold of CTL activation necessary for tumor regression.

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Publishing Authors By Initials

For similar proteins: neoplasm proteins research abstracts see: proteins: neoplasm proteins research

PUBMED ID PMID:

MEDLINE DATE: 1997 Jan-Feb

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The cancer journal from Scientific American

VOLUME: 3

Page Numbers: 37-44

Journal Abbreviation:

ISSN: 1081-4442

DAY: 28

MONTH: 01

YEAR: 2008

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9513568

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Keywords Mesh Terms:

KEYWORDS: Neoplasm Proteins

MESH TERMS: adverse effects

Chemical & Substance for Abstract: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Information

Substance Name: Interferon Type II

Registry Number: 82115-62-6

Grant and Affiliation Information for Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

AFFILIATION: Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Country: UNITED STATES

AGENCY: United States NCI

GRANT: Z01 BC010763-01

ACRONYM: BC

MEDLINETA: Cancer J Sci Am

REFSOURCE: Cancer J Sci Am. 1997 Jan-Feb;3(1):4-5

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A Related Publications

• Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
• Bottom up: a modular view of immunology.
• Cancer immunotherapy: is there real progress at last?
• Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
• Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
• Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
• GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells.
• Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy.
• Helper B Cells Promote Cytotoxic T Cell Survival and Proliferation Independently of Antigen Presentation through CD27/CD70 Interactions.
• High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis.
• Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
• Intensity of the vaccine-elicited immune response determines tumor clearance.
• Migration deficit in monocyte-macrophages in human ovarian cancer.
• Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
• Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
• Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response.
• Spontaneous and treatment-induced cancer rejection in humans.
• The Requirements for CTL-Mediated Rejection of Cancer in Humans: NKG2D and Its Role in the Immune Responsiveness of Melanoma.
• The immunologic constant of rejection.
• Tumour immunity: effector response to tumour and role of the microenvironment.
• Wheat bran biodegradation by Pleurotus ostreatus: A solid-state Carbon-13 NMR study.